X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

KZIA

Closed

Kazia Therapeutics Ltd Adr

6.63
+0.36 (+5.74%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 6.27
Day's Range: 6.01 - 6.645
Send
When Written:
 
1.13
Kazia Therapeutics Ltd is a biotechnology company based in Australia that focuses on the development of innovative cancer therapies. The company's lead product candidate, GDC-0084, is a brain-penetrant small molecule inhibitor of the PI3K/Akt/mTOR pathway, which is being developed for the treatment of glioblastoma multiforme, the most common and aggressive form of primary brain cancer. Kazia Therapeutics also has a preclinical pipeline of potential cancer therapies, including KZ-321, a novel small molecule inhibitor of the DCLK1 kinase, which is being developed for the treatment of colorectal cancer. The company's American Depositary Receipts (ADRs) trade on the NASDAQ exchange under the ticker symbol "KZIA."

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X